These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33732305)

  • 21. Vitreous Inflammatory Cytokines and Chemokines, Not Altered After Preoperative Adjunctive Conbercept Injection, but Associated With Early Postoperative Macular Edema in Patients With Proliferative Diabetic Retinopathy.
    Sun H; Zou W; Zhang Z; Huang D; Zhao J; Qin B; Xie P; Mugisha A; Liu Q; Hu Z
    Front Physiol; 2022; 13():846003. PubMed ID: 35309074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients.
    Funatsu H; Yamashita H; Noma H; Mimura T; Nakamura S; Sakata K; Hori S
    Graefes Arch Clin Exp Ophthalmol; 2005 Jan; 243(1):3-8. PubMed ID: 15258777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of adjunctive intravitreal conbercept at the end of diabetic vitrectomy for the prevention of post-vitrectomy hemorrhage in patients with severe proliferative diabetic retinopathy: a prospective, randomized pilot study.
    Jiang T; Gu J; Zhang P; Chen W; Chang Q
    BMC Ophthalmol; 2020 Feb; 20(1):43. PubMed ID: 32013913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraocular VEGF level as a risk factor for postoperative complications after vitrectomy for proliferative diabetic retinopathy.
    Wakabayashi Y; Usui Y; Okunuki Y; Ueda S; Kimura K; Muramatsu D; Kezuka T; Goto H
    Invest Ophthalmol Vis Sci; 2012 Sep; 53(10):6403-10. PubMed ID: 22899753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy.
    Qian J; Lu Q; Tao Y; Jiang YR
    Retina; 2011 Jan; 31(1):161-8. PubMed ID: 20890241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Succinate increases in the vitreous fluid of patients with active proliferative diabetic retinopathy.
    Matsumoto M; Suzuma K; Maki T; Kinoshita H; Tsuiki E; Fujikawa A; Kitaoka T
    Am J Ophthalmol; 2012 May; 153(5):896-902.e1. PubMed ID: 22265145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
    Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
    Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced Expression of Erythropoietin After Intravitreal Ranibizumab in Proliferative Diabetic Retinopathy Patients-Retrospective Interventional Study.
    Chen L; Feng J; Shi Y; Luan F; Ma F; Wang Y; Yang W; Tao Y
    Front Med (Lausanne); 2021; 8():710079. PubMed ID: 34621759
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of efficacy and safety of intravitreal ranibizumab and conbercept before vitrectomy in Chinese proliferative diabetic retinopathy patients: a prospective randomized controlled trial.
    Li S; Guo L; Zhou P; Tang J; Wang Z; Zhang L; Zhao M; Qu J
    Eye Vis (Lond); 2022 Dec; 9(1):44. PubMed ID: 36451252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy.
    Cui J; Chen H; Lu H; Dong F; Wei D; Jiao Y; Charles S; Gu W; Wang L
    J Ophthalmol; 2018; 2018():4927259. PubMed ID: 30046459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preoperative Timing of Intravitreal Bevacizumab Injection for Proliferative Diabetic Retinopathy Patients.
    Feng J; Li B; Wen J; Jiang Y
    Ophthalmic Res; 2018; 60(4):250-257. PubMed ID: 30380554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytokine levels in the aqueous humor of young and senior patients with proliferative diabetic retinopathy.
    Zhao Q; An W; Han J
    Eur J Ophthalmol; 2022 Sep; ():11206721221129431. PubMed ID: 36163689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab.
    Nonobe NI; Kachi S; Kondo M; Takai Y; Takemoto K; Nakayama A; Hayakawa M; Terasaki H
    Retina; 2009 May; 29(5):579-85. PubMed ID: 19430279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 27‑Gauge vitrectomy vs. 25‑gauge vitrectomy in the management of proliferative diabetic retinopathy with preoperative intravitreal injection of conbercept.
    Xiang W; Fang D; Jiang X; Zhang Z; Xiang C; Huang S; Zhang S; Wei Y
    Exp Ther Med; 2023 Oct; 26(4):472. PubMed ID: 37664677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. INTRAVITREAL CONBERCEPT (KH902) FOR SURGICAL TREATMENT OF SEVERE PROLIFERATIVE DIABETIC RETINOPATHY.
    Su L; Ren X; Wei H; Zhao L; Zhang X; Liu J; Su C; Tan L; Li X
    Retina; 2016 May; 36(5):938-43. PubMed ID: 26630313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What is the impact of intravitreal injection of conbercept on neovascular glaucoma patients: a prospective, interventional case series study.
    Shi L; Yang J; Lin J
    BMC Ophthalmol; 2019 Jun; 19(1):128. PubMed ID: 31185956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in aqueous humor protein profiles in patients with proliferative diabetic retinopathy before and after conbercept treatment.
    Wang T; Chen H; Du X; Li N; Chen Y; Min H
    J Proteomics; 2023 Mar; 276():104838. PubMed ID: 36764651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intraocular Pharmacokinetics and Safety of Subretinal Injection Compared with Intravitreal Application of Conbercept in Vitrectomized Rabbit Eyes.
    Yao TT; Jin XL; Yang Y; Wang YX; Zhou YL; He FL; Wang ZY
    J Ophthalmol; 2020; 2020():2674780. PubMed ID: 32280518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab.
    Ma Y; Zhang Y; Zhao T; Jiang YR
    Am J Ophthalmol; 2012 Feb; 153(2):307-313.e2. PubMed ID: 21982107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of intravitreal ranibizumab pretreatment on vitrectomy in young patients with proliferative diabetic retinopathy.
    Chen HJ; Wang CG; Dou HL; Feng XF; Xu YM; Ma ZZ
    Ann Palliat Med; 2020 Jan; 9(1):82-89. PubMed ID: 32005066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.